Natalia Belousova

Natalia Belousova

Auto-generated profile, based on publicly available information

Natalia Belousova

Department of Pneumology, Foch Hospital, Suresnes, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
QXQingyong Xu
Qingyong Xu
MEMohamed Elrefaei
Mohamed Elrefaei
JTJean-Luc Taupin
Jean-Luc Taupin
KHKelley M.K. Hitchman
Kelley M.K. Hitchman
SHSteven Hiho
Steven Hiho
ARAntoine Roux
Antoine Roux

12 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
ARAntoine Roux
Antoine Roux
VBVincent Bunel
Vincent Bunel
NBNatalia Belousova
Natalia Belousova
JMJonathan Messika
Jonathan Messika
STSébastien Tanaka
Sébastien Tanaka
FPFrancois Parquin
Francois Parquin
Lung transplant candidates who are highly sensitized against human leucocyte antigen present an ongoing challenge with regards to finding immunologically acceptable donors. Desensitization strategies aimed at reducing preformed donor-specific antibodies have a number of limitations. Imlifidase, an IgG-degrading enzyme derived from Streptococcus pyogenes, is a novel agent that has been used to convert positive crossmatches to negative in kidney transplant candidates, allowing transplantation to occur. We present the first case of imlifidase use for antibody depletion in a highly sensitized lung transplant candidate who went on to undergo a successful bilateral lung transplant.

26 December 2022 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
AMAmanda Mac
Amanda Mac
TXTong Xu
Tong Xu
JWJoyce K Y Wu
Joyce K Y Wu
NBNatalia Belousova
Natalia Belousova
HKHaruna Kitazawa
Haruna Kitazawa
CCChung-Wai Chow
Chung-Wai Chow
Rationale: Spirometry and plethysmography are the gold standard pulmonary function tests (PFT) for diagnosis and management of lung disease. Due to the inaccessibility of plethysmography, spirometry is often used alone but this leads to missed or misdiagnoses as spirometry cannot identify restrictive disease without plethysmography. We aimed to develop a deep learning model to improve interpretation of spirometry alone. Methods: We built a multilayer perceptron model using full PFTs from 748 patients, interpreted according to international guidelines. Inputs included spirometry (forced vital capacity, forced expiratory volume in 1 s, forced mid-expiratory flow25–75), plethysmography (total lung capacity, residual volume) and biometrics (sex, age, height). The model was developed with 2582 PFTs from 477 patients, randomly divided into training (80%), validation (10%) and test (10%) sets, and refined using 1245 previously unseen PFTs from 271 patients, split 50/50 as validation (136 patients) and test (135 patients) sets. Only one test per patient was used for each of 10 experiments conducted for each input combination. The final model was compared with interpretation of 82 spirometry tests by 6 trained pulmonologists and a decision tree. Results: Accuracies from the first 477 patients were similar when inputs included biometrics+spirometry+plethysmography (95%±3%) vs biometrics+spirometry (90%±2%). Model refinement with the next 271 patients improved accuracies with biometrics+pirometry (95%±2%) but no change for biometrics+spirometry+plethysmography (95%±2%). The final model significantly outperformed (94.67%±2.63%, p<0.01 for both) interpretation of 82 spirometry tests by the decision tree (75.61%±0.00%) and pulmonologists (66.67%±14.63%). Conclusions: Deep learning improves the diagnostic acumen of spirometry and classifies lung physiology better than pulmonologists with accuracies comparable to full PFTs.

20 April 2022 in Journal of the Association of Medical Microbiology and Infectious Disease Canada
Verified
Journal Article
Closed access
ODOlívia Meira Dias
Olívia Meira Dias
NBNatalia Belousova
Natalia Belousova
NSNadia Sharif
Nadia Sharif
IBIan Brasg
Ian Brasg
LSLianne G Singer
Lianne G Singer
CRColeman Rotstein
Coleman Rotstein
CASE PRESENTATION: A 63-year-old man with a left single lung transplant for end-stage combined restrictive and obstructive lung disease developed persistent pulmonary infiltrates and recurrent gram-negative bacteremia post-transplant. Bronchoalveolar lavage fluid revealed a nematode on Papanicolau staining compatible with Strongyloides stercoralis larvae on day 50 post-transplant. Although Strongyloides serology performed post-transplant was negative, a retrospective review of the medical record revealed marked peripheral blood eosinophilia on several occasions before transplantation. Despite reduction in immunosuppression and treatment with albendazole and ivermectin, the patient developed another episode of Escherichia coli bacteremia. He died 3 months post-transplant from pulmonary and neurological complications. DIAGNOSIS: Strongyloides hyper-infection. DISCUSSION: Strongyloides hyper-infection syndrome is known to occur in immunocompromised patients, but it has only been reported once in a lung transplant recipient. This case illustrates the importance of screening for parasitic infections before transplantation in patients with marked eosinophilia, especially among immigrants from countries in which Strongyloides is endemic. Hyper-infection syndrome may appear years after infection in the context of immunosuppression or immunodeficiency. This case also highlights the association between Strongyloides hyper-infection and bacteremia with enteric organisms.

23 August 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
NBNatalia Belousova
Natalia Belousova
EHElla Huszti
Ella Huszti
QLQixuan Li
Qixuan Li
AVAnastasiia Vasileva
Anastasiia Vasileva
RGRasheed Ghany
Rasheed Ghany
TMTereza Martinu
Tereza Martinu
The Acute Rejection Score (A-score) in lung transplant recipients, calculated as the average of acute cellular rejection A-grades across transbronchial biopsies, summarises the cumulative burden of rejection over time. We assessed the association between A-score and transplant outcomes in two geographically distinct cohorts. The primary cohort included 772 double lung transplant recipients. The analysis was repeated in 300 patients from an independent comparison cohort. Time-dependent multivariable Cox models were constructed to evaluate the association between A-score and CLAD or graft failure. Landmark analyses were performed with A-score calculated at 6 and 12 months post-transplant. In the primary cohort, no association was found between A-score and graft outcome. However, in the comparison cohort, time A-score was associated with CLAD both as a time-dependent variable (HR 1.51, p < 0.01), and when calculated at 6 and 12 months post-transplant. The A-score can be a useful predictor of lung transplant outcomes in some settings but is not generalizable across all centres; its utility as a prognostication tool is therefore limited.

2 July 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MRMarc Raynaud
Marc Raynaud
NBNatalia Belousova
Natalia Belousova
MGMatthieu Glorion
Matthieu Glorion
CHCaroline Hillebrand
Caroline Hillebrand
CPClément Picard
Clément Picard
ARAntoine Roux
Antoine Roux